Clinical Trial Detail

NCT ID NCT03290079
Title Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

neuroendocrine tumor

neuroendocrine carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.